A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants

NCT04840927 | Withdrawn Phase 1

• 3 other identifiers: E7386-E044-002QSC2033352020-005638-13
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The primary purpose of this study is to evaluate the pharmacokinetic (PK) profile of E7386 following oral administration of E7386 enteric coated TR prototype tablet formulations (TR1, TR2 and optional TR3) and to evaluate the relative bioavailability of E7386 TR tablets compared to E7386 IR reference tablet.

Conditions

Healthy Volunteers

Keywords

Relative Bioavailability; Pharmacoscintigraphic; Pharmacokinetic; E7386

Outcome Measures

Primary Outcomes (7)

• Cmax: Maximum Observed Plasma Concentration for E7386

  Day 1: 0-48 hours post-dose

• Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7386

  Day 1: 0-48 hours post-dose

• AUC (0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for E7386

  Day 1: 0-48 hours post-dose

• AUC (0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time for E7386

  Day 1: 0-48 hours post-dose

• T1/2: Terminal Elimination Phase Half-life for E7386

  Day 1: 0-48 hours post-dose

• CL/F: Apparent Total Clearance Following Extravascular Administration for E7386

  Day 1: 0-48 hours post-dose

• Vz/F: Apparent Volume of Distribution at Terminal Phase for E7386

  Day 1: 0-48 hours post-dose

Study Arms (2)

Cohort 1: E7386 40 mg

EXPERIMENTAL

Participants will be randomized to one of the 3 treatment sequences: Treatment sequence 1: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4. Treatment sequence 2: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4. Treatment sequence 3: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4. A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3.

Drug: E7386

Cohort 2: E7386 40 mg

EXPERIMENTAL

Participants will be randomized to one of the 3 treatment sequences: Treatment sequence 4: Participants will receive Regimen C on Day 1 of treatment period 1 then Regimen B on Day 1 of treatment period 2 then Regimen A on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4. Treatment sequence 5: Participants will receive Regimen A on Day 1 of treatment period 1 then Regimen C on Day 1 of treatment period 2 then Regimen B on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4. Treatment sequence 6: Participants will receive Regimen B on Day 1 of treatment period 1 then Regimen A on Day 1 of treatment period 2 then Regimen C on Day 1 of treatment period 3 and an optional Regimen D on Day 1 of an optional treatment period 4. A maximum wash out period of 10 days will be maintained between treatment periods 1, 2 and 3.

Drug: E7386

Interventions

E7386 DRUG

Regimen A: 40 milligram (mg) IR Oral Tablet.

Cohort 1: E7386 40 mg; Cohort 2: E7386 40 mg

Eligibility Criteria

• Age: 30 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female (women of nonchildbearing potential \[WNCBP\]) aged greater than or equal to (\>=) 30 years and less than or equal to (\<=) 55 years old inclusive at the time of signing informed consent
• Body Mass Index (BMI) \>=18.0 and \<=30.0 kilogram per square meter (kg/m\^2) as measured at screening
• Participants must demonstrate their ability to swallow an empty size 000 capsule (26.1\*9.91 millimeter \[mm\]) at screening and must be willing and able to take the SmartPill\^Trade Mark (TM) (27\*12 mm)
• Provide written informed consent
• Willing and able to comply with all aspects of the protocol
• Participant must have regular bowel movements (that is, average stool production of \>=1 and \<=3 stools per day)
• Must agree to adhere to the contraception requirements

You may not qualify if:

• Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 millisieverts (mSv) in the last 12 months or 10 mSv in the last 5 years prior to Day -1 of Period 1. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study
• Male participants with pregnant or breastfeeding partners
• Males who are unwilling to follow the contraception rules of the study for up to 92 days after last dose of the study drug
• Females who are of childbearing potential or breastfeeding or pregnant at screening or admission/predose (as documented by a positive beta-human chorionic gonadotropin \[or human chorionic gonadotropin {hCG} test with a minimum sensitivity of 25 international units per liter {IU/L} or equivalent units of beta-hCG {or hCG}\]. A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug)
• Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
• Evidence of disease that may influence the outcome of the study within 4 weeks of the participants first planned dose; example, disorders of the gastrointestinal (GI) tract especially peptic ulceration, GI bleeding, ulcerative colitis, Crohn's Disease or Irritable Bowel Syndrome, liver, kidney, chronic respiratory system, dermatological system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism. Participants with Gilbert's Syndrome are not allowed
• Any history of GI or abdominal surgery or conditions that may affect absorption, metabolism or excretion of E7386 example, intestinal resections, hepatectomy, nephrectomy, digestive organ resection, fistulas or physiological/mechanical GI obstruction at screening
• Contraindications to SmartPill\^TM use: history of gastric bezoar, swallowing disorders, suspected or known strictures, severe dysphagia to food or pills, Crohn's disease or diverticulitis
• Presence of non-removable metal objects such as metal plates, screws, etc, in the abdominal region of the body. Very small metal items (example, sterilization clips, hernia repair staples) are permitted
• Acute diarrhea or constipation in the 7 days before the predicted Day 1. If screening occurs greater than (\>) 7 days before the Day 1, this criterion will be determined on Day 1. Diarrhea will be defined as the passage of liquid feces and/or a stool frequency of \>3 times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day
• Any abnormal clinical symptom or organ impairment found by medical history at screening, and physical examinations, clinical laboratory tests and vital signs
• Hemoglobin, total white cell count, neutrophils or platelets below the lower limit of normal at screening. Alanine aminotransferase (ALT) \>1.2\*upper limit of normal (ULN) that is, up to 60 IU/L (men) and 42 IU/L (women) at screening
• A prolonged QT/corrected QT (QTc) interval (corrected QT interval by Fridericia's formula \[QTcF\] \>450 millisecond \[msec\]) as demonstrated by a repeated electrocardiogram at screening or baseline or a history of risk factors for torsade de pointes (example, heart failure, hypokalemia, family history of long QT Syndrome) or the use of concomitant medications that prolonged the QT/QTc interval
• Known history of clinically significant drug or food allergies or presently experiencing any seasonal or perennial allergy at screening
• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results at screening

Sponsors & Collaborators

• Eisai Limited: lead

Study Sites (1)

Quotient Sciences

Nottingham, United Kingdom

Location

MeSH Terms

Interventions

E-7386

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 8, 2021
• First Posted: April 12, 2021
• Study Start: April 9, 2021
• Primary Completion: May 17, 2023
• Study Completion: May 17, 2023
• Last Updated: November 24, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will share

Locations

GB (1)